Q32 Bio (QTTB) Research & Development (2017 - 2026)
Q32 Bio's quarterly Research & Development came in at $3.2 million in Q1 2026, down 54.83% year-on-year from $7.1 million in Q1 2025, and down 2.93% quarter-over-quarter from $3.3 million in Q4 2025.
Q32 Bio has reported Research & Development for 10 years, with the latest figure at $3.2 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 54.83% year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (down 66.43% YoY), and the FY2025 full-year result was $19.2 million, down 60.21% from the prior year.
- Research & Development for Q1 2026 stood at $3.2 million, down from $3.3 million in the prior quarter.
- The five-year high for Research & Development was $27.1 million in Q4 2022, with the low at $3.2 million in Q1 2026.
- Average Research & Development over 5 years is $11.8 million, with a median of $8.3 million recorded in 2023.
- Year-over-year, Research & Development soared 92.23% in 2024 and slumped 75.22% in 2025.
- Tracing QTTB's Research & Development over 5 years: stood at $27.1 million in 2022, then plunged by 69.28% to $8.3 million in 2023, then grew by 26.45% to $10.5 million in 2024, then slumped by 68.56% to $3.3 million in 2025, then dropped by 2.93% to $3.2 million in 2026.
- The last three Research & Development figures came in at $3.2 million (Q1 2026), $3.3 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.22 Mn |
| Dec 31, 2025 | 3.32 Mn |
| Sep 30, 2025 | 3.56 Mn |
| Jun 30, 2025 | 5.16 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | 10.55 Mn |
| Sep 30, 2024 | 14.35 Mn |
| Jun 30, 2024 | 13.41 Mn |
| Mar 31, 2024 | 9.84 Mn |
| Dec 31, 2023 | 8.34 Mn |
| Sep 30, 2023 | 7.46 Mn |
| Jun 30, 2023 | 8.02 Mn |
| Mar 31, 2023 | 7.91 Mn |
| Dec 31, 2022 | 27.15 Mn |
| Sep 30, 2022 | 25.85 Mn |
| Jun 30, 2022 | 21.08 Mn |
| Mar 31, 2022 | 24.27 Mn |
| Dec 31, 2021 | 23.65 Mn |
| Sep 30, 2021 | 23.99 Mn |
| Jun 30, 2021 | 23.70 Mn |
| Mar 31, 2021 | 21.76 Mn |
| Dec 31, 2020 | 23.20 Mn |
| Sep 30, 2020 | 20.42 Mn |
| Jun 30, 2020 | 27.47 Mn |
| Mar 31, 2020 | 29.31 Mn |
| Dec 31, 2019 | 20.34 Mn |
| Sep 30, 2019 | 25.69 Mn |
| Jun 30, 2019 | 22.83 Mn |
| Mar 31, 2019 | 20.54 Mn |
| Dec 31, 2018 | 16.28 Mn |
| Sep 30, 2018 | 13.39 Mn |
| Jun 30, 2018 | 10.29 Mn |
| Mar 31, 2018 | 8.00 Mn |
| Dec 31, 2017 | 9.58 Mn |
| Sep 30, 2017 | 4.95 Mn |
| Jun 30, 2017 | 4.06 Mn |
| Mar 31, 2017 | 2.80 Mn |